Hikma Pharmaceuticals Plc (LON:HIK) has earned a consensus rating of “Hold” from the seven analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is GBX 1,728 ($22.58).
Several equities analysts have commented on HIK shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 1,700 ($22.21) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Peel Hunt reissued a “hold” rating on shares of Hikma Pharmaceuticals in a research report on Monday, September 2nd. Finally, Barclays increased their price target on Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) and gave the stock an “equal weight” rating in a research report on Tuesday, August 20th.
Hikma Pharmaceuticals stock traded down GBX 18 ($0.24) during mid-day trading on Friday, hitting GBX 2,023 ($26.43). The company’s stock had a trading volume of 164,680 shares, compared to its average volume of 822,138. The company has a 50 day moving average of GBX 2,049.47 and a 200-day moving average of GBX 1,826.52. The stock has a market cap of $4.90 billion and a PE ratio of 13.60. The company has a debt-to-equity ratio of 37.69, a quick ratio of 0.78 and a current ratio of 1.28. Hikma Pharmaceuticals has a one year low of GBX 1,491.50 ($19.49) and a one year high of GBX 2,212 ($28.90).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Further Reading: NASDAQ
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.